Boston Scientific (BSX) Projected to Announce Quarterly Earnings on Wednesday

Boston Scientific (NYSE:BSX) will likely be posting its Q2 2026 results before the market opens on Wednesday, July 29th. Analysts expect the company to post earnings of $0.83 per share and revenue of $5.3671 billion for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 8:00 AM ET.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. During the same period in the prior year, the firm posted $0.75 earnings per share. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. On average, analysts expect Boston Scientific to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Boston Scientific Stock Performance

NYSE BSX opened at $43.14 on Wednesday. The business’s 50-day moving average price is $47.77 and its 200 day moving average price is $64.93. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. Boston Scientific has a twelve month low of $42.20 and a twelve month high of $109.50. The company has a market capitalization of $64.12 billion, a PE ratio of 18.05, a price-to-earnings-growth ratio of 0.84 and a beta of 0.58.

Boston Scientific announced that its board has approved a stock repurchase plan on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Analyst Ratings Changes

A number of research firms recently issued reports on BSX. Oppenheimer set a $90.00 target price on shares of Boston Scientific in a report on Thursday, April 23rd. Jefferies Financial Group cut their price target on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research note on Wednesday, June 24th. Barclays decreased their price target on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a report on Thursday, May 28th. Stifel Nicolaus lowered their price objective on shares of Boston Scientific from $75.00 to $65.00 and set a “buy” rating for the company in a research note on Thursday, June 25th. Finally, Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $79.84.

Insiders Place Their Bets

In other Boston Scientific news, Director David C. Habiger purchased 2,250 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The shares were bought at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the transaction, the director owned 13,878 shares in the company, valued at $776,057.76. This represents a 19.35% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Cheryl Pegus purchased 1,770 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average cost of $56.49 per share, with a total value of $99,987.30. Following the completion of the acquisition, the director directly owned 1,770 shares in the company, valued at approximately $99,987.30. This trade represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 9,800 shares of company stock valued at $554,012 over the last 90 days. 0.34% of the stock is owned by company insiders.

Institutional Investors Weigh In On Boston Scientific

Institutional investors and hedge funds have recently bought and sold shares of the business. CYBER HORNET ETFs LLC increased its position in shares of Boston Scientific by 3.4% during the 3rd quarter. CYBER HORNET ETFs LLC now owns 4,004 shares of the medical equipment provider’s stock worth $391,000 after purchasing an additional 132 shares during the last quarter. Gerber Kawasaki Wealth & Investment Management boosted its stake in shares of Boston Scientific by 4.7% during the 4th quarter. Gerber Kawasaki Wealth & Investment Management now owns 3,082 shares of the medical equipment provider’s stock worth $294,000 after acquiring an additional 139 shares during the period. Manhattan West Asset Management LLC increased its holdings in shares of Boston Scientific by 8.3% during the 2nd quarter. Manhattan West Asset Management LLC now owns 2,302 shares of the medical equipment provider’s stock worth $247,000 after acquiring an additional 176 shares during the last quarter. Reynders McVeigh Capital Management LLC boosted its holdings in shares of Boston Scientific by 6.3% during the 3rd quarter. Reynders McVeigh Capital Management LLC now owns 3,099 shares of the medical equipment provider’s stock worth $303,000 after buying an additional 185 shares during the period. Finally, HM Payson & Co. lifted its holdings in Boston Scientific by 3.0% during the 4th quarter. HM Payson & Co. now owns 6,892 shares of the medical equipment provider’s stock worth $657,000 after purchasing an additional 198 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.